- Company
- About Us
- Management Team
- Board of Directors
- Collaborations
- Careers
- Contact Us
- Science
- Onco-Metabolism Platform
- Therapeutic Areas
- Publications
- Programs
- Pipeline
- Glutaminase Inhibitor Telaglenastat
- Arginase Inhibitor INCB001158
- Arginase Inhibitor
CB-280 - CD73 Inhibitor
CB-708 - IL4I1 Inhibitor
- Clinical Trials
- Clinical Trials Overview
- Expanded Access
- Media & Investors
- Corporate Profile
- Press Releases
- Event & Presentations
- Stock Information
- Financial Information
- Overview
- SEC Filings
- Ownership Summary
- Analyst Coverage
- Corporate Governance
- Highlights
- Board of Directors
- Management Team
- Committee Composition
- Shareholder Services
Science
Publications and Presentations
Check out our publications and poster presentations.
September 2019
ENTRATA: Randomized, double-blind, phase 2 study of telaglenastat + everolimus vs. placebo + E in patients with advanced/metastatic renal cell carcinomaEuropean Society for Medical Oncology
April 2019
Reversal of adenosine-mediated immune suppression by CB-708, an orally bioavailable and potent small molecule inhibitor of CD73American Association of Cancer Research
February 2019
Telaglenastat(CB-839), a glutaminase inhibitor, in combination with cabozantinib in patients with clear cell and papillary metastatic renal cell cancer (mRCC): Results of a Phase 1 studyAmerican Society of Clinical Oncology Genitourinary Cancer Symposium
February 2019
CANTATA: Randomized, global, double-blind study of telaglenastat (CB-839) plus cabozantinib vs. cabozantinib plus placebo in patients with metastatic renal cell carcinomaAmerican Society of Clinical Oncology Genitourinary Cancer Symposium
December 2018
Our Pipeline
We are focused on novel treatments for
cancer and other life-threatening diseases.